Therefore, MAFLD diagnosis requires the presence of hepatic steatosis by using histological , imaging (ultrasound), or blood biomarker (e.g., ALT) tests, combined with altered corporeal fat accumulation/distribution, alterations in glucose homeostasis (prediabetes or type 2 Diabetes Mellitus “T2DM”), or evidence of MetS [9]. This evidence concerns the gene GPT and type 2 diabetes mellitus.